Outputs (4)

Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2024)
Journal Article
Ferreri, A., Illerhaus, G., Doorduijn, J., Auer, D., Bromberg, J., Calimeri, T., Cwynarski, K., Fox, C., Hoang-Xuan, K., Malaise, D., Ponzoni, M., Schorb, E., Soussain, C., Specht, L., Zucca, E., Buske, C., Jerkeman, M., & Dreyling, M. (2024). Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 35(6), 491-507. https://doi.org/10.1016/j.annonc.2023.11.010

Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy (2023)
Journal Article
Cornell, I., Al Busaidi, A., Wastling, S., Anjari, M., Cwynarski, K., Fox, C. P., Martinez-Calle, N., Poynton, E., Maynard, J., & Thust, S. C. (2023). Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy. Journal of Personalized Medicine, 13(7), Article 1182. https://doi.org/10.3390/jpm13071182

Primary Central Nervous System Lymphoma (PCNSL) is a highly malignant brain tumour. We investigated dynamic changes in tumour volume and apparent diffusion coefficient (ADC) measurements for predicting outcome following treatment with MATRix chemothe... Read More about Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy.

A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial (2021)
Journal Article
Fox, C. P., Ali, A. S., McIlroy, G., Thust, S., Martinez-Calle, N., Jackson, A. E., …Cwynarski, K. (2021). A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial. Blood Advances, 5(20), 4073-4082. https://doi.org/10.1182/bloodadvances.2021004779

Relapsed or refractory primary central nervous system lymphoma (rrPCNSL) confers a poor prognosis with no accepted standard of care. Very few prospective studies have been conducted in this patient group. This study was a multicenter phase 1/2 study... Read More about A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial.

Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG) (2021)
Journal Article
Barajas, R. F., Politi, L. S., Anzalone, N., Schöder, H., Fox, C. P., Boxerman, J. L., …Hu, L. S. (2021). Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro-Oncology, 23(7), 1056-1071. https://doi.org/10.1093/neuonc/noab020

Advanced molecular and pathophysiologic characterization of primary central nervous system lymphoma (PCNSL) has revealed insights into promising targeted therapeutic approaches. Medical imaging plays a fundamental role in PCNSL diagnosis, staging, an... Read More about Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG).